These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 10667233

  • 1. The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities.
    Feldkamp MM, Lau N, Guha A.
    Ann N Y Acad Sci; 1999; 886():257-60. PubMed ID: 10667233
    [No Abstract] [Full Text] [Related]

  • 2. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM, Lau N, Guha A.
    Oncogene; 1999 Dec 09; 18(52):7514-26. PubMed ID: 10602510
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620.
    Kurimoto M, Hirashima Y, Hamada H, Kamiyama H, Nagai S, Hayashi N, Endo S.
    J Neurooncol; 2003 Jan 09; 61(2):103-12. PubMed ID: 12622448
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB.
    Clin Cancer Res; 2005 Apr 15; 11(8):3045-54. PubMed ID: 15837760
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.
    Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP.
    Blood; 2000 Jan 15; 95(2):639-45. PubMed ID: 10627474
    [Abstract] [Full Text] [Related]

  • 9. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 10. Farnesyltransferase inhibitors.
    Adjei AA.
    Cancer Chemother Biol Response Modif; 2001 Jun 05; 19():149-64. PubMed ID: 11686012
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro.
    Kopec M, Strusinska K, Legat M, Makowski M, Jakobisiak M, Golab J.
    Oncol Rep; 2004 May 05; 11(5):1127-31. PubMed ID: 15069557
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.
    Girgert R, Wittrock J, Pfister S, Schweizer P.
    J Cancer Res Clin Oncol; 2003 Apr 05; 129(4):227-33. PubMed ID: 12700894
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.